Strong revenue momentum Veracyte, now including C2i Genomics, reported quarterly revenue growth with a 15% uplift and testing revenue up by 19%, indicating a growing demand for its diagnostic offerings and potential cross-sell opportunities to existing C2i Genomics customers.

Expanded test portfolio Recent launches include TrueMRD recurrence-monitoring for muscle-invasive bladder cancer, Prosigna LDT in the US, and tests identifying breast cancer patients who may avoid chemotherapy, presenting upsell and adjacent-market opportunities in urology and breast cancer risk assessment.

Key leadership momentum New chief of development and technology officer appointed to oversee end-to-end product development, signaling a focus on accelerating diagnostic assays, software, and bioinformatics—a potential entry point for collaboration on integrated solutions.

Strategic events access Active participation and data sharing at ASCO and ASCO GU, with launches tied to major conferences, suggesting opportunities to engage clinicians and hospital systems around premier diagnostic tools and MRD capabilities.

Growth runway Funding level shown (112M) alongside modest current revenue band (1M–10M) and a relatively small employee base, indicating a scalable organization with potential partner-driven pilots, channel partnerships, and joint ventures to accelerate market penetration.